A5012538161- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Inflammatory Biomarkers in Disease Prognosis
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- PI3K/AKT/mTOR signaling in cancer
- Renal cell carcinoma treatment
- Neuroendocrine Tumor Research Advances
- Angiogenesis and VEGF in Cancer
- Monoclonal and Polyclonal Antibodies Research
- Lymphatic System and Diseases
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Glioma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Neutropenia and Cancer Infections
- Lipid metabolism and disorders
- Healthcare professionals’ stress and burnout
Regione Campania
2022-2023
Ospedale Santa Maria
2021
University of Campania "Luigi Vanvitelli"
2013-2020
University of Naples Federico II
2013-2019
Mechanisms of acquired resistance to trastuzumab-based treatment in gastric cancer are largely unknown. In this study, we analyzed 22 pairs tumor samples taken at baseline and post-progression patients receiving chemotherapy trastuzumab for advanced HER2-positive [immunohistochemistry (IHC) 3+ or 2+ with in-situ hybridization (ISH) amplification] gastroesophageal cancers. Strict clinical criteria defining were adopted. Loss HER2 positivity loss over-expression defined as post-trastuzumab IHC...
Abstract Purpose: Refining the selection of HER2-positive metastatic gastric cancer patient candidates for trastuzumab is a challenge precision oncology. Preclinical studies have suggested several genomic mechanisms primary resistance, leading to activation tyrosine kinase receptors other than HER2 or downstream signaling pathways. Experimental Design: We carried out this multicenter, prospective, case-control study demonstrate negative predictive impact panel candidate alterations (AMNESIA...
Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a randomized phase III trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed superior activity and efficacy in first-line treatment compared alone.Nab-P not dispensed Italy; however, we obtained this drug from our Ethics Committee for compassionate use. The aim study was to evaluate the safety profile Nab-P cohort patients treated outside clinical trials. From January 2012 May 2014, included 41 advanced...
Background . High neutrophil to lymphocyte ratio (NLR) has shown be a predictor of poor outcomes in various malignancies, including pancreatic cancer. Methods We assessed 70 consecutive pts with histologically confirmed mPC who received chemotherapy nab-paclitaxel/gemcitabine at two different European oncologic centers between January 2012 and November 2015. Variables for prognostic correlations included age ≥ 66, sex, Karnofsky PS score, primary tumor site, baseline CA19.9 level 59xULN,...
Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) after failure prior with Sunitinib or cytokine. The present study Italian Multi-Institutional Retrospective Analysis that evaluated the outcomes Axitinib, in second-line mRCC. medical records 62 patients treated were retrospectively reviewed. Progression Free Survival (PFS), Overall (OS), Objective Response Rate (ORR), Disease Control (DCR), and safety profile axitinib...
Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel in geriatric population. Our study aims to show whether this schedule can be feasible elderly as first-line mPC.We retrospectively analyzed 64 mPC patients (≥65 years old) treated according MPACT schedule.Median age was 69.5 (range, 65-80 years); after a median 5 cycles administered 1-12), most common adverse events...
Increased insulin-like growth factor (igf) signalling has been observed in breast cancer, including endocrine-responsive cancers, and linked to disease progression recurrence. In particular, igf-1 the ability induce promote lymphangiogenesis through induction of vascular endothelial C (vegfc). present study, we analyzed serum tumour samples from 60 patients with endocrine-positive cancer determine expression possible relationship circulating igf-1, igf binding protein 3 (igfbp3), vegfc...
Aim: Systemic inflammatory response affects survival of gastric cancer (GC) patients. This study was carried out to create a prognostic inflammatory-based score predict in metastatic GC (mGC) before first-line chemotherapy. Materials & methods: We studied the value neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte 151 patients with mGC at diagnosis. Results: Median overall (OS) significantly lower high NLR. Performance status 1–2 according Eastern Cooperative Oncology Group scale NLR...
Background: To date, few studies of preoperative chemotherapy or chemoradiotherapy (crt) in gastroesophageal junction (gej) cancer have been statistically powered; indeed, gej tumours thus far grouped with esophageal gastric phase iii trials, thereby generating conflicting results. Methods: We studied 41 patients affected by locally advanced Siewert type i and ii adenocarcinoma who were treated a neoadjuvant crt regimen [folfox4 (leucovorin–5-fluorouracil–oxaliplatin) for 4 cycles,...
Patients with advanced gastric cancer have a relatively poor prognosis few therapeutic alternatives beyond first-line therapy. The purpose of this manuscript is to highlight the potential for prolonged responses in patients HER-2-positive disease. Patients, materials & methods: We analyzed data diagnosed HER-2-positive-advanced who progressed on trastuzumab-based combination therapy and subsequently received second-line consisting ramucirumab paclitaxel.Most had stable disease after...
Purpose: ATTRACTION-2 trial assessed the role of Nivolumab as a new standard treatment for Asian patients with pretreated metastatic gastric cancer (mGC). The aim this analysis was to evaluate safety and efficacy in real-life Western population, considering lack evidence date. Patients Methods: progressed after ≥ 2 chemotherapy regimens able receive (3 mg/kg q14) were eligible analysis. Results: 16 received third (81.3%) or fourth line (18.7%) from September 2017 July 2019. literature only...
Gefitinib is a tyrosine kinase inhibitor, indicated in advanced non-small cell lung cancer all lines of treatment for patients harboring EGFR mutations. It has favorable toxicity profile but may induce unexpected adverse effects, such as an infiammatory reaction the bladder. We report rare case hemorrhagic cystitis, unusual side effect, patient with treated gefitinib, which did not compromise clinical response.
The anti-HER2 monoclonal antibody trastuzumab is a key drug for the treatment of HER2-positive gastric cancer (GC); however, its activity often limited by onset resistance and mechanisms are still poorly understood. Several targeted agents showed synergistic concomitant use with in vitro under clinical investigation. aim this study was to assess antitumor duligotuzumab, an anti HER3/EGFR or ipatasertib, AKT inhibitor, combined panel human cells (GCC), efficacy such combinations...
The combination of trifluridine-tipiracil and bevacizumab was compared with monotherapy in a randomized, open-label, phase II trial, resulting statistically significant clinically relevant improvement progression-free survival (PFS), tolerable toxicity patients refractory metastatic colorectal cancer (mCRC); however, evidence supporting the role this real-world setting is limited. aim our work to provide further on activity safety series Western mCRC or intolerant previous therapies. We...
Background: The prognosis of patients with advanced gastric cancer remains overall poor despite some recent innovations and the development new therapeutic approaches. Current European guidelines do not recommend any specific treatment for refractory to two or more previous chemotherapy regimens, making this setting "orphan." Immunotherapy is quickly evolving also malignancy even if controversial results correct patient selection still debated, especially Western patients. phase III...
Bone metastasis is an uncommon event in advanced gastric cancer patients and bone metastases are rarely detected as isolated lesions. However, eleven years after treatment for locally cancer, including total gastrectomy followed by adjuvant chemotherapy, a 49-year-old female was admitted to the IX Division of General Surgery Second University Naples (Naples, Italy) exhibiting severe progressive neurological symptoms. Magnetic resonance imaging indicated vertebral abnormalities, with evidence...